https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302022-10-01 12:00:412025-06-24 17:40:21Unblinded clinical trial data confirmed that both dosage groups of BB-101 effectively improved ulcer area and severity.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302022-01-01 12:00:122025-06-24 17:42:39Commissioned a certified ISO manufacturer to develop microneedle products for cosmetic applications.
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302021-12-01 12:00:232025-06-27 09:36:52Completed subject recruitment for BB-101 Phase I clinical trial; Data and Safety Monitoring Board reported no safety concerns.
Unblinded clinical trial data confirmed that both dosage groups of BB-101 effectively improved ulcer area and severity.
Cosmetic microneedle passed INCI registration.
Commissioned a certified ISO manufacturer to develop microneedle products for cosmetic applications.
Completed subject recruitment for BB-101 Phase I clinical trial; Data and Safety Monitoring Board reported no safety concerns.